Repotrectinib
This page contains brief information about repotrectinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Repotrectinib is approved to treat:
- Non-small cell lung cancer that has spread and has an abnormal ROS1 gene. It is used in adults.
- Solid tumors that have an NTRK gene fusion. It is used in adults and children aged 12 years and older whose cancer has spread or cannot be removed by surgery and got worse after other treatment or cannot be treated with other therapies.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that repotrectinib provides a clinical benefit in these patients.
Repotrectinib is also being studied in the treatment of other types of cancer.
More About Repotrectinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Repotrectinib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Repotrectinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.